Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 31,492 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the sale, the senior vice president directly owned 300,760 shares of the company’s stock, valued at $1,930,879.20. This represents a 9.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

CytomX Therapeutics Price Performance

Shares of CTMX stock traded up $0.37 during trading hours on Thursday, reaching $4.77. The company had a trading volume of 13,412,791 shares, compared to its average volume of 6,618,611. CytomX Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $8.21. The business has a fifty day simple moving average of $5.27 and a 200-day simple moving average of $4.10. The company has a market cap of $810.96 million, a price-to-earnings ratio of -119.13 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The company had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. On average, equities research analysts expect that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC purchased a new position in CytomX Therapeutics in the third quarter valued at about $25,000. Wells Fargo & Company MN increased its stake in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the last quarter. Invesco Ltd. purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $32,000. Pursue Wealth Partners LLC bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several firms raised ratings and price targets (notably Barclays to $16/”Overweight”, Guggenheim to $15/”Buy”, Wedbush to $11), sending bullish signals about the company’s pipeline value and upside potential. Barclays/Tickerreport coverage
• Neutral Sentiment: CytomX priced a large underwritten equity offering to raise roughly $250M (45.99M shares at $5.30 and pre-funded warrants), which materially boosts cash runway to fund programs but also dilutes existing holders; the deal includes a 30‑day option for additional shares. Globe Newswire: Offering Pricing
• Neutral Sentiment: Additional media coverage and filings reflect the equity raise (reports cite $234M–$250M sizes and pricing at $5.30), confirming strong capital access but increasing share count. TipRanks: Equity Offering
• Neutral Sentiment: Reported short interest data appears negligible/erroneous (shows 0 shares), so short‑seller pressure is not a clear factor in today’s move. (No external article link available for the short interest snapshot.)
• Negative Sentiment: Recent quarterly results disappointed consensus (EPS and revenue misses reported), a headwind that analysts have noted and that could temper enthusiasm despite upgrades. Earnings Miss Article
• Negative Sentiment: HC Wainwright cut near‑term EPS forecasts substantially (larger FY2026/FY2027 losses now modeled), highlighting higher expected burn even with new capital — a negative for near‑term profitability metrics. HC Wainwright Estimates Summary
• Negative Sentiment: Independent commentary (Seeking Alpha) cautions that early clinical data may not justify elevated valuation levels, suggesting upside may be tied to significant trial progress rather than near‑term fundamentals. Seeking Alpha: Valuation Caution

Analyst Ratings Changes

CTMX has been the subject of several analyst reports. JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the company from $7.00 to $12.00 in a report on Monday. Barclays upped their price objective on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday. Oppenheimer reissued an “outperform” rating and set a $12.00 target price on shares of CytomX Therapeutics in a research report on Monday. HC Wainwright upped their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a report on Monday. Finally, Jefferies Financial Group increased their price target on CytomX Therapeutics from $8.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.22.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.